Father–Son COVID‐19‐associated mucormycosis: Important role of genetic susceptibility in combination with environmental factors

In this report, a father with a history of diabetes mellitus and his son without a remarkable past medical history, both got COVID‐19‐ associated mucormycosis (CAM) as evidenced by their clinical and radiological findings. This suggests the possible role of genetics in combination with the environment in susceptibility to CAM.

[1]  R. Mohammadi,et al.  From Bilateral Periorbital Necrotic Wound to Fungal Brain Abscess: A Complicated Case of COVID-19-Associated Mucormycosis , 2022, Case reports in infectious diseases.

[2]  E. Duarte,et al.  COVID-19: impact on Public Health and hypothesis-driven investigations on genetic susceptibility and severity , 2022, Immunogenetics.

[3]  W. Jantarabenjakul,et al.  Host genetic factors of COVID-19 susceptibility and disease severity in a Thai population , 2022, Journal of Human Genetics.

[4]  J. Perfect,et al.  The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries , 2022, The Lancet Microbe.

[5]  M. Pourazizi,et al.  COVID-19 Associated Mucormycosis and Anbarnesa: Concerning about Important Source of Spores , 2022, Iranian journal of public health.

[6]  Rachana Shah,et al.  Incidence, cumulative mortality and factors affecting the outcome of COVID-19-associated mucormycosis from Western India , 2021, Indian journal of ophthalmology.

[7]  H. Banna,et al.  Global Prevalence of COVID-19-Associated Mucormycosis (CAM): Living Systematic Review and Meta-Analysis , 2021, Journal of fungi.

[8]  D. Corzo-Leon,et al.  COVID‐19–associated mucormycosis, diabetes and steroid therapy: Experience in a single centre in Western Mexico , 2021, Mycoses.

[9]  R. Ozaras,et al.  COVID-19-associated mucormycosis: Case report and systematic review , 2021, Travel Medicine and Infectious Disease.

[10]  J. Baddley,et al.  COVID-19 associated Mucormycosis (CAM): risk factors and mechanisms of disease , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  S. Rudramurthy,et al.  Epidemiology and Pathophysiology of COVID-19-Associated Mucormycosis: India Versus the Rest of the World , 2021, Mycopathologia.

[12]  A. Roychoudhury,et al.  Current Understanding in the Pathophysiology of SARS-CoV-2-Associated Rhino-Orbito-Cerebral Mucormycosis: A Comprehensive Review , 2021, Journal of Maxillofacial and Oral Surgery.

[13]  Michael Berk,et al.  Genetic gateways to COVID‐19 infection: Implications for risk, severity, and outcomes , 2020, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[14]  R. Lu,et al.  A case of invasive pulmonary mucormycosis resulting from short courses of corticosteroids in a well-controlled diabetic patient , 2020, Medical mycology case reports.

[15]  S. Rudramurthy,et al.  A multicenter observational study on the epidemiology, risk factors, management and outcomes of mucormycosis in India. , 2019, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[16]  W. Lim,et al.  Dexamethasone in Hospitalized Patients with Covid-19 , 2021 .